The stock of 89bio Inc (ETNB) has gone up by 6.32% for the week, with a -31.11% drop in the past month and a -6.06% drop in the past quarter. The volatility ratio for the week is 9.29%, and the volatility levels for the past 30 days are 12.47% for ETNB. The simple moving average for the past 20 days is -14.39% for ETNB’s stock, with a -29.06% simple moving average for the past 200 days.
Is It Worth Investing in 89bio Inc (NASDAQ: ETNB) Right Now?
ETNB has 36-month beta value of 1.53. Analysts have mixed views on the stock, with 8 analysts rating it as a “buy,” 1 as “overweight,” 2 as “hold,” and 0 as “sell.”
The public float for ETNB is 140.33M, and currently, short sellers hold a 10.85% ratio of that float. The average trading volume of ETNB on April 17, 2025 was 2.68M shares.
ETNB) stock’s latest price update
The stock of 89bio Inc (NASDAQ: ETNB) has decreased by -2.64 when compared to last closing price of 6.05.Despite this, the company has seen a gain of 6.32% in its stock price over the last five trading days. zacks.com reported 2025-03-06 that Here is how 89BIO (ETNB) and Eton Pharmaceuticals, Inc. (ETON) have performed compared to their sector so far this year.
Analysts’ Opinion of ETNB
Many brokerage firms have already submitted their reports for ETNB stocks, with Goldman repeating the rating for ETNB by listing it as a “Neutral.” The predicted price for ETNB in the upcoming period, according to Goldman is $11 based on the research report published on March 14, 2025 of the current year 2025.
Citigroup, on the other hand, stated in their research note that they expect to see ETNB reach a price target of $25. The rating they have provided for ETNB stocks is “Buy” according to the report published on March 13th, 2025.
ETNB Trading at -30.84% from the 50-Day Moving Average
After a stumble in the market that brought ETNB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -50.25% of loss for the given period.
Volatility was left at 12.47%, however, over the last 30 days, the volatility rate increased by 9.29%, as shares sank -32.99% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -45.21% lower at present.
During the last 5 trading sessions, ETNB rose by +6.32%, which changed the moving average for the period of 200-days by -26.47% in comparison to the 20-day moving average, which settled at $6.88. In addition, 89bio Inc saw -24.68% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at ETNB starting from QUOC LE-NGUYEN, who proposed sale 15,329 shares at the price of $5.95 back on Apr 15 ’25. After this action, QUOC LE-NGUYEN now owns shares of 89bio Inc, valued at $91,171 using the latest closing price.
RA CAPITAL MANAGEMENT, L.P., the Director of 89bio Inc, purchase 5,714,285 shares at $8.75 during a trade that took place back on Jan 30 ’25, which means that RA CAPITAL MANAGEMENT, L.P. is holding 19,554,319 shares at $49,999,994 based on the most recent closing price.
Stock Fundamentals for ETNB
The total capital return value is set at -0.87. Equity return is now at value -78.34, with -68.30 for asset returns.
Based on 89bio Inc (ETNB), the company’s capital structure generated 0.09 points at debt to capital in total, while cash flow to debt ratio is standing at -9.8. The debt to equity ratio resting at 0.09. The interest coverage ratio of the stock is -72.71.
Currently, EBITDA for the company is -384.66 million with net debt to EBITDA at 0.25. The liquidity ratio also appears to be rather interesting for investors as it stands at 13.19.
Conclusion
To put it simply, 89bio Inc (ETNB) has had a bad performance in recent times. Analysts have a bullish opinion on the stock, with some rating it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
